Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 75/100

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Wednesday, February 25, 2026 1 min read
Key Takeaway: Radiopharm Theranostics has successfully dosed its first patient in the Phase 1/2a clinical study of BetaBart (RV-01). This milestone follows the recent IND approval from the US FDA, allowing the company to explore the therapeutic potential of targeting B7H3. The study aims to assess the safety and efficacy of this innovative treatment.
Price reaction · baseline $5.2 (2026-02-25T19:31:00.000Z) · hit during market hours · 1 other RADX headline(s) in the window, move may be shared
day 0 close · peak
-1.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • First patient dosed in Phase 1/2a study, indicating progress.
  • BetaBart (RV-01) targets B7H3, a promising therapeutic approach.
  • IND approval from the FDA highlights regulatory support.

Full Press Release Details

• Announcements , Updates
• PDF
• February 25, 2026
Loading Viewer…

More Announcements & Updates

• Announcements
• December 22, 2023
• Announcements
• August 4, 2022
• Announcements
• October 19, 2022
• Announcements
• October 9, 2023

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the BetaBart (RV-01) study about?

The BetaBart (RV-01) study aims to evaluate the safety and efficacy of targeting B7H3.

When was the first patient dosed in the study?

The first patient was dosed in the Phase 1/2a clinical study on February 25, 2026.

What regulatory approval did Radiopharm receive?

Radiopharm received IND approval from the US FDA to initiate the clinical study.

What phase is the BetaBart study currently in?

The BetaBart study is currently in Phase 1/2a.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a B7H3
Last updated: Feb 25, 2026